Literature DB >> 31610178

Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice.

Jing Qi1, Jong-Won Kim1, Zixiong Zhou1, Chae-Woong Lim1, Bumseok Kim2.   

Abstract

Oxidative stress and its associated lipid peroxidation play a key role in nonalcoholic steatohepatitis (NASH). Ferroptosis is a recently recognized type of cell death characterized by an iron-dependent and lipid peroxidation-mediated nonapoptotic cell death. We demonstrate the impact of ferroptosis on the progression of NASH induced by methionine/choline-deficient diet (MCD) feeding for 10 days. RSL-3 (a ferroptosis inducer) treatment showed decreased hepatic expression of glutathione peroxidase 4 (GPX4) and conversely increased 12/15-lipoxygenase, and apoptosis-inducing factor, indicating that ferroptosis plays a key role in NASH-related lipid peroxidation and its associated cell death. Consistently, levels of serum biochemical, hepatic steatosis, inflammation, and apoptosis in MCD-fed mice were exacerbated with RSL-3 treatment. However, MCD-fed mice treated with sodium selenite (a GPX4 activator) showed increase of hepatic GPX4, accompanied by reduced NASH severity. To chelate iron, deferoxamine mesylate salt was used. Administration of deferoxamine mesylate salt significantly reduced NASH severity and abolished the harmful effects of RSL-3 in MCD-fed mice. Finally, treatment with liproxstatin-1 (a ferroptosis inhibitor) repressed hepatic lipid peroxidation and its associated cell death, resulting in decreased NASH severity. Consistent with the in vivo findings, modulation of ferroptosis/GPX4 affected hepatocellular death in palmitic acid-induced in vitro NASH milieu. We conclude that GPX4 and its related ferroptosis might play a major role in the development of NASH.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31610178     DOI: 10.1016/j.ajpath.2019.09.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis.

Authors:  Gai Gao; Zhishen Xie; Er-Wen Li; Yong Yuan; Yu Fu; Pan Wang; Xiaowei Zhang; Yonghui Qiao; Jiangyan Xu; Christian Hölscher; Hui Wang; Zhenqiang Zhang
Journal:  J Nat Med       Date:  2021-02-15       Impact factor: 2.343

2.  Transcriptomic analysis in zebrafish larvae identifies iron-dependent mitochondrial dysfunction as a possible key event of NAFLD progression induced by benzo[a]pyrene/ethanol co-exposure.

Authors:  Muhammad Imran; Frédéric Chalmel; Odile Sergent; Bertrand Evrard; Hélène Le Mentec; Antoine Legrand; Aurélien Dupont; Maëlle Bescher; Simon Bucher; Bernard Fromenty; Laurence Huc; Lydie Sparfel; Dominique Lagadic-Gossmann; Normand Podechard
Journal:  Cell Biol Toxicol       Date:  2022-04-12       Impact factor: 6.691

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

4.  Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.

Authors:  Jiahao Xu; Xing Wu; Xiaoyan Wang
Journal:  Biochem Genet       Date:  2022-09-12       Impact factor: 2.220

5.  Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Antonella Vetuschi; Alfredo Cappariello; Paolo Onori; Eugenio Gaudio; Giovanni Latella; Simona Pompili; Roberta Sferra
Journal:  Eur J Histochem       Date:  2022-06-21       Impact factor: 1.966

Review 6.  Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.

Authors:  Jianan Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-05-07       Impact factor: 5.787

7.  ENO3 promoted the progression of NASH by negatively regulating ferroptosis via elevation of GPX4 expression and lipid accumulation.

Authors:  Di Lu; Qiaoyun Xia; Zhiyu Yang; Shanjun Gao; Suofeng Sun; Xiaoying Luo; Zhen Li; Xiulei Zhang; Shuangyin Han; Xiuling Li; Mingbo Cao
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization?

Authors:  Jia-Yue Duan; Xiao Lin; Feng Xu; Su-Kang Shan; Bei Guo; Fu-Xing-Zi Li; Yi Wang; Ming-Hui Zheng; Qiu-Shuang Xu; Li-Min Lei; Wen-Lu Ou-Yang; Yun-Yun Wu; Ke-Xin Tang; Ling-Qing Yuan
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 9.  From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.

Authors:  Peng Zhao; Alan R Saltiel
Journal:  J Biol Chem       Date:  2020-07-10       Impact factor: 5.157

Review 10.  The role of regulated necrosis in endocrine diseases.

Authors:  Wulf Tonnus; Alexia Belavgeni; Felix Beuschlein; Graeme Eisenhofer; Martin Fassnacht; Matthias Kroiss; Nils P Krone; Martin Reincke; Stefan R Bornstein; Andreas Linkermann
Journal:  Nat Rev Endocrinol       Date:  2021-06-16       Impact factor: 47.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.